PT - JOURNAL ARTICLE AU - Nicolas Veyres AU - Adjia Hamadjida AU - Philippe Huot TI - Predictive value of parkinsonian primates in pharmacological studies, a comparison between the macaque, marmoset and squirrel monkey AID - 10.1124/jpet.117.247171 DP - 2018 Jan 01 TA - Journal of Pharmacology and Experimental Therapeutics PG - jpet.117.247171 4099 - http://jpet.aspetjournals.org/content/early/2018/03/09/jpet.117.247171.short 4100 - http://jpet.aspetjournals.org/content/early/2018/03/09/jpet.117.247171.full AB - The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate is the gold-standard animal model of Parkinson's disease (PD) and has been used to assess the effectiveness of experimental drugs on dyskinesia, parkinsonism and psychosis. Three species have been used in the majority of studies, the macaque, marmoset and squirrel monkey, the latter much less so than the first 2 species. However, the predictive rate of each species at forecasting clinical efficacy, or lack thereof, is poorly documented. Here, we have reviewed all the published literature detailing pharmacological studies that assessed the effects of experimental drugs on dyskinesia, parkinsonism and psychosis in each of these species and have calculated their predictive rate of success and failure at the clinical level. We found that, for dyskinesia, the macaque has a positive predictive rate of 87.5% and a false positive rate of 38.1%, while the marmoset has a positive predictive rate of 76.9% and a false positive rate of 15.6%. For parkinsonism, the macaque has a positive predictive rate of 68.2% and a false positive rate of 44.4%, while the marmoset has a positive predictive rate of 86.9% and a false positive rate of 41.7%. No drug that alleviates psychosis in the clinic has shown efficacy at doing so in the macaque, while the marmoset has 100% positive predictive rate. The small number of studies conducted in the squirrel monkey precluded us from calculating its predictive efficacy. We hope that our results will help in the design of pharmacological experiments and will facilitate the drug discovery and development process in PD.